DNA methyltransferase inhibitors and the development of epigenetic cancer therapies

Journal of the National Cancer Institute

Volumn 97, Issue 20, 2005, Pages 1498-1506

  Lyko, Frank ^a   Brown, Robert ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CARBOPLATIN; CISPLATIN; DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; EPIRUBICIN; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; INTERFERON; METHYLTRANSFERASE INHIBITOR; MG 98; PROCAINAMIDE; PROCAINE; RG 108; TEMOZOLOMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZEBULARINE; ANTINEOPLASTIC ANTIMETABOLITE; DNA;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DNA METHYLATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY CANCER; LOW DRUG DOSE; LUNG CANCER; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA AND VOMITING; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SICKLE CELL ANEMIA; STRUCTURE ANALYSIS; TREATMENT OUTCOME; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 27144509196     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji311     Document Type: Review

References (83)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
2. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2004 Nov 19; [Epub ahead of print].
3. Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 2003;19:269-77.
4. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293: 1074-80.
5. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002;3:662-73.
6. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002;295:1079-82.
7. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002;21:5400-13.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
9. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
10. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 2002;12:373-9.
11. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
12. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964;20:202-3.
13. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
14. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7.
15. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974;30:405-22.
16. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res 1984;8:1043-9.
17. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-86.
18. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003;109:89-102.
19. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56.
20. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994;91:11797-801.
21. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002;321:591-9.
22. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
23. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005;11:3862-8.
24. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004;6:151-8.
25. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004;62:204-11.
26. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70.
27. Nakagawa H, Hasumi K, Woo JT, Nagai K, Wachi M. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis 2004;25:1567-74.
28. Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis 1998;19:597-604.
29. Siedlecki P, Boy RG, Comagic S, Schirrmacher R, Wiessler M, Zielenkiewicz P, et al. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochem Biophys Res Commun 2003;306:558-63.
30. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305-11.
31. Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, Cornblatt BS, et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res 2001;61:8611-6.
32. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003;63:4984-9.
33. Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, Esteller M, Serrano M. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 2004;23:735-43.
34. Pina IC, Gautschi JF, Wang GY, Sanders ML, Schmitz FJ, France D, et al. Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003;68:3866-73.
35. Flynn J, Fang JY, Mikovits JA, Reich NO. A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase. J Biol Chem 2003;278:8238-43.
36. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-5.
37. Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB, Schuebel KE. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 2004;36:582-4.
38. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
39. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
40. Xiong Z, Laird PW. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-4.
41. Ramsahoye BH. Measurement of genome wide DNA methylation by reversed-phase high-performance liquid chromatography. Methods 2002;27:156-61.
42. Fraga MF, Uriol E, Diego LB, Berdasco M, Esteller M, Canal MJ, et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: Application to plant, animal and human cancer tissues. Electrophoresis 2002;23:1677-81.
43. Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Dohner H, Wiessler M, et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003;31:e2.
44. Adorjan P, Distler J, Lipscher E, Model F, Muller J, Pelet C, et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 2002;30:e21.
45. Shi H, Maier S, Nimmrich I, Yan PS, Caldwell CW, Olek A, et al. Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem 2003;88:138-43.
46. Mund C, Beier V, Bewerunge P, Dahms M, Lyko F, Hoheisel JD. Array-based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines. Nucleic Acids Res 2005;33:e73.
47. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
48. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic dna methylation. J Clin Oncol 2005;23:3897-905.
49. De Smet C, De Backer P, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996;93:7149-53.
50. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781-90.
51. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005;65:7086-90.
52. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64.
53. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
54. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101.
55. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99:3905-8.
56. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004;6:361-71.
57. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
58. Trinh BN, Long TI, Nickel AE, Shibata D, Laird PW. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol 2002;22:2906-17.
59. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92.
60. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358-68.
61. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249:135-64.
62. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2′- deoxycytidine in solid tumors. Curr Opin Investig Drugs 2002;3:627-33.
63. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
64. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998;84:87-9.
65. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones PA. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999;19:6690-8.
66. Velicescu M, Weisenberger DJ, Gonzales FA, Tsai YC, Nguyen CT, Jones PA. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 2002;62:2378-84.
67. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
68. Lin KT, Momparler RL, Rivard GE. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981;70:1228-32.
69. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6.
70. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
71. Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M. Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res 1990;50:4572-7.
72. Lenzi R, Raber MN, Gravel D, Frost P, Abbruzzese JL. Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2′-deoxy-5-azacytidine. Int J Oncol 1995;6:447-50.
73. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000;18:83-91.
74. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
75. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
76. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23: 4225-31.
77. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-8.
78. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005;4:549-51.
79. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4:351-8.
80. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10:4420-6.
81. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002;8:2246-52.
82. Lyko F, Stach D, Brenner A, Stilgenbauer S, Dohner H, Wirtz M, et al. Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis 2004;25:1530-5.
83. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: Potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004;7:267-78.